top of page

Clinical Trial 1

Published in The Journal of Clinical Psychiatry, 330 Adult Patient, Randomized, Double-Blind Placebo-Controlled Study

EnLyte has been clinically shown to improve depressive symptoms in patients with Major Depressive Disorder (MDD) and who also tested positive for an MTHFR polymorphism. Patients had a 75% improvement and 42% remission rate.

Clinical Trial 2

Conducted at Massachusetts General Hospital in conjunction with Harvard University

Results suggest EnBrace HR (EnLyte) is a well-tolerated intervention with potential efficacy for the prevention and treatment of perinatal depression.

Sad children

Case Series Report

Coenzyme Treatment of Childhood and Adolescent Depression: A Case Series

Clearly, there is a need for safe alternatives to standard medications for our youngest patients. We report the use of EnLyte, a vitamin-based “coenzyme therapy,” in twenty-two children and teens with major depression.

Children in Science Class

Case Series Addendum

A 7 Case Report Series on Children and Adolescents and ADHD using EnLyte

The following cases highlight that a comprehensive approach to ADHD can lead to significant improvement across multiple symptoms, beyond just attention and behavior control.

Woman Sleeping

EnLyte Sleep Study

An Open-Label Study of EnLyte® in a Psychiatric Outpatient Population who are MTHFR Heterozygous or Homozygous Variant with co-Occurring Disturbed Sleep

Patients took the EnLyte® in an open label manner for 4-weeks. Most patients reported their sleep was significantly improved.

Sad on Couch

Journal of Addictions and Therapies

The Prevalence and Role of MTHFR Polymorphisms in Opiate Dependency
 

"We screened consecutively admitted patients who were dependent on heroin and/or other opiates, for C677T and A1298C polymorphisms. Over a six-month period, 86 of 96, or 90% of subjects, were positive for at least one of these MTHFR variants".

bottom of page